Integra Lifesciences Holdings (IART) Cost of Revenue (2009 - 2026)

Integra Lifesciences Holdings has disclosed Cost of Revenue across 18 years of filings, most recently posting $199.0 million for Q2 2026.

• In Q2 2026, Cost of Revenue fell 3.52% year-over-year to $199.0 million; the TTM figure through Jun 2026 stood at $783.1 million (up 1.88% YoY), while the FY2025 annual figure was $803.6 million, up 10.32% from the prior year.
• Cost of Revenue came in at $199.0 million for Q2 2026 at Integra Lifesciences Holdings, up from $174.9 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $214.1 million in Q4 2025 to a low of $142.6 million in Q1 2022.
• Average Cost of Revenue over 5 years is $175.0 million, with a median of $174.6 million recorded in 2023.
• Year-over-year, Cost of Revenue gained 17.41% in 2023 and slipped 7.06% in 2026.
• Over 5 years, Cost of Revenue stood at $147.9 million in 2022, then grew by 15.28% to $170.5 million in 2023, then advanced by 13.5% to $193.6 million in 2024, then climbed by 10.58% to $214.1 million in 2025, then fell by 7.03% to $199.0 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $199.0 million in Q2 2026, $174.9 million in Q1 2026, and $214.1 million in Q4 2025.